Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication’s issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

<table>
<thead>
<tr>
<th>Bone Marrow Transplant</th>
<th>Gynecologic</th>
<th>Immunotherapy</th>
<th>Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Head &amp; Neck</td>
<td>Melanoma/Skin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hematology</td>
<td>Neuro-Oncology</td>
<td>Thoracic</td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bone Marrow Clinical Trials

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**BONE MARROW TRANSPLANT**

**STUDY 2015-115**

Phase II

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

**STUDY 2018-084**

Phase I/II

A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

**STUDY BMTCTN1506**

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.
STUDY 2018-128
Phase II
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

STUDY 2017-081
Phase III
Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

STUDY NEW 2014-103
Phase I/II
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

STUDY 2016-049
Phase I/II
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

STUDY 2011-086
NA
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

IMMUNOTHERAPY
STUDY 2018-008
Phase III
A Phase 3, Randomized, Open-Label Study of Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Breast Clinical Trials
For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVANT
STUDY NRG-BR003
Phase III
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

STUDY A011502
Phase III
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Study Code</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEOADJUVANT STUDY RTOG1304 Phase III</td>
<td></td>
<td></td>
<td>NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.</td>
</tr>
<tr>
<td>STUDY S1418 Phase III</td>
<td></td>
<td></td>
<td>A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with &gt; 1 cm Residual Invasive Cancer or Positive Lymph Nodes (&gt;pN1mic) After Neoadjuvant Chemotherapy.</td>
</tr>
<tr>
<td>ADVANCED (STAGE IV) CHEMOTHERAPY STUDY 2017-129</td>
<td></td>
<td></td>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.</td>
</tr>
<tr>
<td>STUDY 2018-009 Phase II</td>
<td></td>
<td></td>
<td>A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer.</td>
</tr>
<tr>
<td>STUDY 2018-015 Phase I/II</td>
<td></td>
<td></td>
<td>A Phase 1b/2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-054 Phase I</td>
<td></td>
<td></td>
<td>A Phase 1a/1b Study of FPA150, and Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors</td>
</tr>
</tbody>
</table>
OTHERS

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY S1501
Phase III
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

STUDY 2017-073
Phase II
The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with Early Stage Breast Cancer

STUDY A011401
Phase III
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-018
Phase I
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

STUDY NEW EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2018-006
NA
Educational Interventions to Promote Tobacco Cessation Among Women Seeking Mammography Screening

STUDY 2018-062
NA
Reducing Metabolic Syndrome and Unmet needs Among Rural Breast Cancer Survivors During the Survivorship Transistion

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2016-037
Phase I
A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

RETURN TO TOP
For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**GASTRIC AND GASTROESOPHAGEAL JUNCTION**

**Metastatic**

**STUDY 2016-210**

**Phase I/II**

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2017-150**

**Phase I/II**

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

**STUDY 2017-149**

**Phase I**

A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer

**STUDY 2017-029**

**Phase I**

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

**STUDY 2016-003**

**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

**STUDY 2016-037**

**Phase I**

A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2018-047**

**Phase II**

A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Unresectable Gastic or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

**PANCREAS**

**Adenocarcinoma**

**Locally Advanced Unresectable**

**STUDY 2018-048**

**Phase III**

PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and nab-Paclitaxel for Font-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma

**Metastatic**

**STUDY 2017-069**

**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2017-075**

**Phase I**

**STUDY 2016-116**
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

**STUDY 2018-090**
Phase III
A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

**HCC**
Adjuvant
**STUDY RTOG1112**
Phase III
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma

**BILIARY/GALL BLADDER**
Metastatic
**STUDY 2017-101**
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

**STUDY 2014-081**
Phase II
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy

**COLON**
Adjuvant
**STUDY A021502**
Phase III
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair

**Metastatic (Includes Rectal)**
1st Line
**STUDY NRG-GI004**
Phase III
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

**Metastatic (Includes Rectal)**
2nd Line
**STUDY 2016-055**
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY S1613</td>
<td>Phase II</td>
<td>A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification</td>
</tr>
<tr>
<td>STUDY 2016-185</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-021</td>
<td>Phase II</td>
<td>A Phase 2, Multicenter, Open-Label Study of DS-8201A in Subjects with HER2- Expressing Advanced Colorectal Cancer</td>
</tr>
<tr>
<td>STUDY 2016-003</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizmab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-129</td>
<td>NA</td>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasability and Utilization of an Application-based Question Prompt List</td>
</tr>
<tr>
<td>RECTUM</td>
<td>STUDY 2017-129</td>
<td>NA Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasability and Utilization of an Application-based Question Prompt List</td>
</tr>
<tr>
<td>STUDY EA2165</td>
<td>Phase II</td>
<td>A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</td>
</tr>
<tr>
<td>STUDY NRG-GI002</td>
<td>Phase II</td>
<td>A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer</td>
</tr>
<tr>
<td>ANAL</td>
<td>Metastatic</td>
<td></td>
</tr>
<tr>
<td>STUDY EA2165</td>
<td>Phase II</td>
<td>A Randomized PHase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</td>
</tr>
<tr>
<td>STUDY 2018-122</td>
<td>Phase II</td>
<td></td>
</tr>
</tbody>
</table>
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipiilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

**NEUROENDOCRINE TUMORS AND CARCINOID**
**STUDY 2017-144**  
**Pilot**  
Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using alpha-[11C]methyl-L-tryptophan (AMT)-PET

**IMAGING STUDIES**
**Metastatic**
**STUDY 2018-171**  
**Phase II**  
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

**OTHER**
**STUDY NEW EAY131**  
**Phase II**  
Molecular Analysis for Therapy Choice (MATCH)

**RETURN TO TOP**

---

**Genitourinary Clinical Trials**

For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

**RENAL**
**STUDY 2016-003**  
**Phase I/II**  
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

**STUDY 2016-037**  
**Phase I**  
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

**STUDY 2018-024**  
**Phase II**  
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

**STUDY S1500**  
**Phase II**  
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

**STUDY 2017-082**  
**Phase I/II**  
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
STUDY NEW 2018-131
Phase II
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-058
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

STUDY 2016-201
Phase III
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).

STUDY 2017-111
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2016-211
Phase II
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY EA8143
Phase III
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-074
Phase II
A Phase 2, Open Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin-Ineligible Urothelial Cancer

STUDY 2018-018
Phase I/II
An Open Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
**STUDY 2018-098**
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

**PROSTATE**
**STUDY NEW 2013-108**
NA
Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer

**STUDY 2016-157**
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

**STUDY NRG-GU002**
Phase II/III
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

**STUDY 2018-124**
Phase I/II
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

**STUDY NEW S1802**
Phase III
Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.

**STUDY NEW 2017-126**
Phase II
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

**STUDY EA8153**
Phase II
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: Phase II the CHAARTED2 Trial

**STUDY RTOG0924**
Phase III
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

**STUDY 2015-135**
Phase II
Phase II Trial of Immune Checkpoint Inhibitor with Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.

**STUDY 2017-092**
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

**STUDY 2015-167**
Phase II
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

**STUDY 2017-046**
<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase IB Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Androgen Deprivation Therapy and Other Agents in Subjects with Castrate Resistant Prostate Cancer (CRPC)</td>
<td>Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy</td>
</tr>
<tr>
<td>STUDY 2015-029</td>
<td>STUDY 2018-015</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
<td>A Phase II Open-Label, a Multisite Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY 2017-156</td>
<td>STUDY NRG-GU005</td>
</tr>
<tr>
<td>Phase II</td>
<td>Phase III</td>
</tr>
<tr>
<td>A Phase II Open-Label, a Multicenter Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer</td>
<td>Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer</td>
</tr>
<tr>
<td>STUDY 2017-129</td>
<td>STUDY 2018-017</td>
</tr>
<tr>
<td>NA</td>
<td>Phase II</td>
</tr>
<tr>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List</td>
<td>A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Doxetaxel, or Enzalutamide in Men with Castration Resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint Pathway and NivoluMAb Clinical Trial Evaluation 9KD)</td>
</tr>
<tr>
<td>STUDY 2018-092</td>
<td>STUDY 2018-092</td>
</tr>
<tr>
<td>Phase III</td>
<td>Phase III</td>
</tr>
<tr>
<td>An international, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of Lu-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-resistant Prostate Cancer (mCRPC)</td>
<td>An international, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of Lu-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-resistant Prostate Cancer (mCRPC)</td>
</tr>
</tbody>
</table>

**BLADDER**

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
<td>Phase II Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>STUDY 2017-070</td>
</tr>
<tr>
<td>Phase I</td>
<td>Phase II</td>
</tr>
<tr>
<td>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</td>
<td>Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]</td>
</tr>
<tr>
<td>STUDY 2016-195</td>
<td>STUDY 2018-110</td>
</tr>
<tr>
<td>Phase II</td>
<td>Phase II</td>
</tr>
<tr>
<td>Phase II Trial of Concurrent Nivolumab in UroThelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]</td>
<td>A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma</td>
</tr>
<tr>
<td>STUDY 2016-195</td>
<td>STUDY 2016-003</td>
</tr>
<tr>
<td>STUDY</td>
<td>Phase</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>2017-092</td>
<td>I/II</td>
</tr>
<tr>
<td>2017-069</td>
<td>I/II</td>
</tr>
<tr>
<td>2017-029</td>
<td>I</td>
</tr>
<tr>
<td>2017-075</td>
<td>I</td>
</tr>
<tr>
<td>2016-175</td>
<td>II</td>
</tr>
<tr>
<td>2016-157</td>
<td>I</td>
</tr>
<tr>
<td>2018-044</td>
<td>II</td>
</tr>
<tr>
<td>2018-015</td>
<td>I/II</td>
</tr>
<tr>
<td>2017-101</td>
<td>I/II</td>
</tr>
<tr>
<td>2016-037</td>
<td>I</td>
</tr>
<tr>
<td>2018-023</td>
<td>I/II</td>
</tr>
<tr>
<td>2018-098</td>
<td>I</td>
</tr>
</tbody>
</table>
OTHER
STUDY NEW EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PE Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

RETURN TO TOP

Gynecologic Clinical Trials

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

CERVIX
STUDY 2017-010
Phase II
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

STUDY 2018-103
Phase III
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

OVARY
STUDY 2017-075
Phase I
A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers

STUDY GOG-3020
Phase III
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

STUDY 2018-043
Phase III
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

STUDY NRG-GY009
Phase II/III
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP Supplied Atezolizumab Versus Pegylated Liposomal
Doxirubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

**STUDY 2016-037**  
Phase I  
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

**STUDY 2018-054**  
Phase I  
A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Solid Advanced Tumors

**STUDY 2018-015**  
Phase I/II  
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

**STUDY 2017-029**  
Phase I  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy of BI 754091 In Patients With Advanced Solid Tumors

**OTHER**  
**STUDY NEW EAY131**  
Phase II  
Molecular Analysis for Therapy Choice (MATCH)

**STUDY 2018-054**  
Phase I  
A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

---

**Return to Top**

---

**Head & Neck Clinical Trials**

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form.](#)

**STAGES I/II/III**  
**STUDY 2016-093**  
Phase I/II  
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

**STUDY EA3132**  
Phase II  
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

**STUDY 2016-133**  
Phase II  
A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With (131) I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
STUDY 2017-157  
Stage III  
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for A Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

STUDY EA3163  
Phase II  
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

STUDY 2017-042  
Phase I/II  
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer

STUDY RTOG1008  
Phase II/III  
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

ANY STAGE  
STUDY 2016-212  
Phase II  
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-107  
Phase III  
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942(Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-069  
Phase I/II  
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-149  
Phase I/II  
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STUDY 2016-017  
Phase I/II  
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2018-098  
Phase I/II  
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

OTHER  
STUDY NEW EAY131  
Phase II  
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2016-055
### Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2018-171**  
**Phase II**  
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

**STUDY 2017-101**  
**Phase I/II**  
A Dose-Finding Pase I Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

**STUDY 2016-037**  
**Phase 1**  
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

---

**Hematology Clinical Trials**

For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**MULTIPLE MYELOMA**  
**STUDY 2012-122**  
**Phase I/II**  
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma

**STUDY 2016-120**  
**Phase I**  
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma

**STUDY 2014-090**  
**Phase I**  
A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

**STUDY 2016-062**  
**Phase I/II**  
Phase 1/2 Trial of Idasanutlin in Combination with Ixazomib and Dexamethasone in Patients with 17p Deleted, Relapsed Phase I/II Multiple Myeloma

**STUDY 2017-136**  
**Pilot**  
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients with Relapsed and/or Refractory Multiple Myeloma

**STUDY NEW 2017-151**  
**Phase IV**  
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)
**STUDY 2018-014**  
**Phase I**  
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

**STUDY 2018-028**  
**Phase II**  
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens

**STUDY 2016-086**  
**Phase I**  
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

**STUDY 2017-024**  
**Phase II**  
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab

**STUDY 2018-026**  
**Phase II**  
A Phase II Study of CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

**AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE**

**STUDY 2012-066**  
**Phase III**  
A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

**STUDY 2016-200**  
**Phase II**  
A Randomized Phase 2 Trial of Revlimid/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide followed by Revlimid/ Dexamethasone/Elotuzumab Maintenance as Second-line Therapy for Patients with Relapsed AL Amyloidosis

**STUDY S1702**  
**Phase II**  
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated Phase II AL Amyloidosis

**STUDY 2017-067**  
**Phase III**  
Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

**STUDY 2016-060**  
**Phase I**  
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123x CD3 DouBody in Subjects with Relapsed or Refractory AML

**LEUKEMIA**

**Acute Lymphoblastic Leukemia (ALL)**

**STUDY E1910**  
**Phase III**  
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABLnegative B lineage Acute Lymphoblastic Leukemia in Adults
Acute Myeloid Leukemia (AML)
STUDY BMTCN1506
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2018-027
Phase I/II
A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy

STUDY 2017-119
Phase III
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects < or = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

STUDY 2017-120
Phase III
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

STUDY 2016-035
Phase I
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

STUDY 2016-103
Phase I
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)
STUDY 2014-132
Phase III
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

STUDY A041702
Phase III
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (greater than or equal to 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Chronic Myeloid Leukemia (CML)
STUDY 2015-128
Phase II
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

LYMPHOMA
Hodgkin’s
STUDY 2017-132
Phase II
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

STUDY 2017-100
Phase III
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivolumAb clinical Trial Evaluation 812)

STUDY NEW 2016-033
Phase II
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma

Non-Hodgkin’s
Aggressive (Mantle Cell, Large B-Cell Lymphoma)
STUDY 2017-025
Phase III
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2017-125
Phase III
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing The Efficacy And Safety Of Polatuzumab Vedotin In Combination With Rituximab And Ohp (R-Chp) Versus Rituximab And Chop (R-Chop) In Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

STUDY 2015-150
Phase I/II
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

STUDY 2018-008
Phase III
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloeucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

STUDY 2014-132
Phase III
A Phase 3b, Multicenter, Open-Label, PCI-32765 (Ibrutinib) Long-term Extension Study

T cell
STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2016-056
Phase II
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

STUDY 2018-003
Phase I
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma
STUDY NEW 2017-008  
Phase I  
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas

STUDY 2017-069  
Phase I/II  
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-037  
Phase I  
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

MYELODYSPLASTIC SYNDROME (MDS)  
STUDY 2016-035  
Phase I  
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Study 2018-027  
Phase I/II  
A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naive Patients Not Eligible for Intensive Induction Therapy

STUDY 2018-068  
Phase I/II  
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

OTHER  
STUDY 2013-113  
Phase II  
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

STUDY NEW EAY131  
Phase II  
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Immunotherapy Clinical Trials

For more information on Immunotherapy Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

IMMUNOTHERAPY  
STUDY 2018-015  
Phase I/II  
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors
# Melanoma/Skin Clinical Trials

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

## ADJUVANT
### STUDY NEW 2018-095
**Phase III**
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

## ADVANCED
### STUDY 2016-210
**Phase I/II**
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

### STUDY 2017-029
**Phase I**
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

### STUDY 2017-069
**Phase I/II**
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

### STUDY 2016-037
**Phase I**
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

### STUDY EA6134
**Phase III**
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

### STUDY 2013-047
**Phase I**
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

### STUDY 2016-017
**Phase I/II**
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

### STUDY 2018-098
**Phase I/II**
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

## OTHER
### STUDY 2017-029
Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

ALL SOLID TUMORS

STUDY 2017-111
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2017-122
Phase I
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2018-019
Phase I
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

STUDY 2017-084
Phase I
<table>
<thead>
<tr>
<th>Study Number</th>
<th>Category</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1b Multi-Indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies</td>
<td>STUDY 2016-170</td>
<td>Phase I/II A Phase I/II, Open-Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy</td>
</tr>
<tr>
<td>Phase I/II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies</td>
<td>STUDY 2016-210</td>
<td>Phase I/II An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zeiloraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
</tr>
<tr>
<td>A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
<td>STUDY 2018-034</td>
<td>Phase I</td>
</tr>
<tr>
<td>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</td>
<td>STUDY 2016-185</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
<td>STUDY 2017-088</td>
<td>Phase I</td>
</tr>
<tr>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors</td>
<td>STUDY 2017-052</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
<td>STUDY 2016-157</td>
<td>Phase I</td>
</tr>
<tr>
<td>A Phase 1/1b Open-Label Multi-Center to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Metastatic or Locally-Advanced Solid Tumor or Lymphoma</td>
<td>STUDY NEW 2018-154</td>
<td>Phase I</td>
</tr>
<tr>
<td>Phase I/II Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy</td>
<td>STUDY NEW 2018-139</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors</td>
<td>STUDY NEW 2018-158</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors</td>
<td>STUDY 2016-042</td>
<td>Phase I</td>
</tr>
</tbody>
</table>
STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2016-075
Phase I/II
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

STUDY 2017-146
Phase 1
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

STUDY 2018-066
Phase I
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

STUDY 2018-035
Phase I
A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2017-101
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

STUDY 2018-125
Phase II
eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study in Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

TUMOR SPECIFIC
STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2016-120
Phase I/II
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas
STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-075
Phase I
A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers

STUDY 2017-018
Phase I
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

GENOMIC TESTING SPECIFIC
STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

RETURN TO TOP

Sarcoma Clinical Trials
There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.
## Thoracic Clinical Trials

For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

### MAINTENANCE

**STUDY NRG-LU002**  
**Phase II/III**  

### STAGE I/II

**STUDY 2016-110**  
**Phase II**  
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

**STUDY 2018-074**  
**Phase II**  
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin-Ineligible Urothelial Cancer

**STUDY 2018-098**  
**Phase I/II**  
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted in Adult Patients with Selected Solid Tumors

### STAGE III A/B

**STUDY 2016-110**  
**Phase II**  
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

**STUDY 2017-152**  
**Phase II**  
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

**STUDY 2018-120**  
**Phase I/II**  
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

**STUDY S1400**  
**Phase II/III**  
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

**STUDY NEW 2018-065**  
**Phase II**  
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

**STUDY 2018-015**
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY NEW S1900A
Phase II
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

STUDY 2018-060
Phase II
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin-Ineligible Urothelial Cancer

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STAGE IV
ALK
STUDY 2018-080
Phase II
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

EGFR
STUDY 2017-145
Phase II
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Other Genetic Marker
STUDY S1400
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

STUDY 2017-145
Phase II
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

STUDY NEW S1900A
Phase II
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

STUDY NEW 2018-065
Phase II
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors
<table>
<thead>
<tr>
<th>Year</th>
<th>Study Number</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>120</td>
<td>I/II</td>
<td>Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma</td>
</tr>
<tr>
<td>2018</td>
<td>111</td>
<td>I</td>
<td>Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>2016</td>
<td>017</td>
<td>I/II</td>
<td>A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies</td>
</tr>
<tr>
<td>2016</td>
<td>055</td>
<td>I</td>
<td>Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>2014</td>
<td>002</td>
<td>II</td>
<td>A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens</td>
</tr>
<tr>
<td>2016</td>
<td>037</td>
<td>I</td>
<td>A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2018</td>
<td>053</td>
<td>III</td>
<td>METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>2018</td>
<td>098</td>
<td>I/II</td>
<td>A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors</td>
</tr>
<tr>
<td>2018</td>
<td>015</td>
<td>I/II</td>
<td>Phase 1b/2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab In Combination with The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>2017</td>
<td>129</td>
<td>NA</td>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List</td>
</tr>
<tr>
<td>2018</td>
<td>074</td>
<td>II</td>
<td>A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin- Ineligible Urothelial Cancer</td>
</tr>
<tr>
<td>2018</td>
<td>098</td>
<td>I/II</td>
<td>A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors</td>
</tr>
</tbody>
</table>
RECURRENT ALK
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Other Genetic Marker
STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY NEW 2018-065
Phase II
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

MESOTHELIOMA
STUDY 2018-105
Phase II
Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma

OTHER
STUDY NEW EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2018-081
Phase I
A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations

STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipiilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

RETURN TO TOP

Karmanos Cancer Institute
4100 John R
Detroit, Michigan 48201
1-800-KARMANOS
(1-800-527-6266)
karmanos.org

To refer a patient or for more information on open clinical trials at the Karmanos Cancer Institute, call 1-800-Karmanos
(1-800-527-6266)

To schedule an appointment, please call between 7:30 AM â€“ 5:30 PM, Monday â€“ Friday

SUBSCRIBE TO KARMANOS CLINICAL TRIALS

©2016 Karmanos Cancer Institute

This email was sent to lowed@karmanos.org. To ensure that you continue receiving our emails, please add us to your address book or safe list.

manage your preferences | opt out using TrueRemove®.

Got this as a forward? Sign up to receive our future emails.